Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 5/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17007235 | 0.80 | DAO (0.40) | HCRTR1PTGS1PTGS2OPRK1HTT | |
| SCHEMBL17028070 | 0.77 | GLS (0.43) | HCRTR1HCRTR2GLSNOS3NOS2 | |
| SCHEMBL9148834 | 0.75 | ACP3 (0.47) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL9146458 | 0.74 | PTGS2 (0.52) | HCRTR1HCRTR2PTGS1PTGS2OPRK1 | |
| SCHEMBL17007104 | 0.71 | HCRTR1 (0.51) | HCRTR1HCRTR2GLSNOS3NOS2 | |
| SCHEMBL28399404 | 0.71 | ACP3 (0.46) | PTGS1PTGS2KMT2A | |
| SCHEMBL17007252 | 0.71 | HCRTR1 (0.48) | HCRTR1HCRTR2GLSNOS3NOS2 | |
| SCHEMBL28184633 | 0.71 | PTGS1 (0.49) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL25145644 | 0.70 | MAPK1 (0.55) | HCRTR1HCRTR2NOS3NOS2MAPK1 | |
| SCHEMBL11791384 | 0.70 | KDM4E (0.46) | PTGS1PTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | disclosed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | disclosed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3107898-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-9156829-B2 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9156829-B2 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9156829-B2 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| WO-2015124932-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | disclosed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | disclosed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885GLS 1818/4885 |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885GLS 1836/4885 |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885GLS 1836/4885 |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885GLS 1818/4885 |
| US-20150232460-A1 | NOVEL COMPOUNDS | CNKSR1, RDX, RB1 | HCRTR1 631/4885HCRTR2 1815/4885GLS 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.